Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.68 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3670066 | 0.91 | SMN1; SMN2 (0.72) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL12189683 | 0.90 | PTPN1 (0.67) | HDAC1HDAC2HDAC8HDAC6KMT2A | |
| SCHEMBL12189596 | 0.90 | KMT2A (0.70) | HDAC1HDAC2HDAC8HDAC6KMT2A | |
| SCHEMBL22191811 | 0.89 | MEN1 (0.78) | HDAC1HDAC2HDAC8HDAC6KMT2A | |
| SCHEMBL3675929 | 0.89 | TP53 (0.86) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL8374911 | 0.87 | HDAC1 (0.85) | HDAC1HDAC2HDAC8HDAC6KMT2A | |
| SCHEMBL12189605 | 0.86 | SMN1; SMN2 (0.62) | HDAC1HDAC2HDAC8HDAC6KMT2A | |
| SCHEMBL12189607 | 0.86 | PGR (0.72) | HDAC8KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL24118803 | 0.85 | MEN1 (0.62) | HDAC1HDAC2HDAC8HDAC6KMT2A | |
| SCHEMBL31224910 | 0.85 | KMT2A (0.71) | KMT2AMEN1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250073242-A1 | SLC26A3 INHIBITORS AND USE THEREOF | UNIV CALIFORNIA (US) | 2025-03-06 | — | — | US | disclosed |
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2021-12-23 | — | — | US | disclosed |
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2021-12-23 | — | — | US | disclosed |
| US-20210179600-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 | Hepagene Therapeutics (HK) Limited (HK) | 2021-06-17 | — | — | US | disclosed |
| EP-1089988-B1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7345174-B2 | Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| EP-1089988-A4 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2005-01-19 | — | — | EP | disclosed |
| CN-1185259-C | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2005-01-19 | — | — | CN | disclosed |
| US-6639023-B1 | Such as 4-hydroxy, sulfonic acid or sulfonyl chloride-2,3,5,6-tetrafluorobenzamidomethyl-polystyrene resin; solid phase synthesis | AVENTIS PHARMACEUTICALS INC. | 2003-10-28 | — | — | US | disclosed |
| CN-1306524-A | Fluorophenyl resin compounds | AVENTIES PHARMACEUTICALS INC (US) | 2001-08-01 | — | — | CN | disclosed |
| EP-1089988-A1 | FLUOROPHENYL RESIN COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067228-A1 | FLUOROPHENYL RESIN COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5977105-A | Compounds | ASTRA PHARMAEUTICALS LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| CN-1208403-A | Compounds | BRITISH ASTRA PHARMACEUTICALS (GB) | 1999-02-17 | — | — | CN | disclosed |
| EP-0865431-A2 | COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997020815-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSP90AB1, HSP90AB2P | HDAC1 1829/4885HDAC2 3624/4885HDAC8 3046/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 13/4885HDAC8 17/4885 |
| US-20250073242-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, ORAI3 | HDAC1 3206/4885HDAC2 2874/4885HDAC8 3943/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | HDAC1 3/4885HDAC2 13/4885HDAC8 17/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | HDAC1 285/4885HDAC2 589/4885HDAC8 405/4885 |
| US-20210179600-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS INHIBITORS OF ASK1 | IRAK1, IRAK2, IRAK3 | HDAC1 279/4885HDAC2 984/4885HDAC8 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.